[Form 4] BIOLARGO, INC. Insider Trading Activity

Rhea-AI Filing Summary

Christina Elaine Bray, a director of Biolargo, Inc. (BLGO), received an option to purchase 110,294 shares of common stock at an exercise price of $0.17 per share on 09/30/2025. The option is exercisable on 09/30/2025 and expires on 09/30/2035. The filing reports that the option was issued as payment for $18,750 in director fees under the issuer's 2024 Equity Incentive Plan. After this grant, Ms. Bray beneficially owns 1,164,025 shares of Biolargo common stock, held directly. The Form 4 was executed on 10/02/2025 and filed under Section 16 reporting requirements.

Positive

• Equity payment for fees: Option issued in exchange for $18,750 in director fees, aligning interests
• Clear grant terms disclosed: 110,294 options at $0.17 strike, exercisable 09/30/2025, expiring 09/30/2035
• Post-grant ownership disclosed: Reporting person beneficially owns 1,164,025 shares (direct)

Negative

• None.

Insights

Corporate Governance Specialist

Director received equity rather than cash for board fees, aligning pay with shareholder interests.

The filing shows the company issued an option grant to a director in lieu of $18,750 of fees, using the 2024 Equity Incentive Plan. Equity-based compensation for board service is a common governance practice to align directors with shareholders because it ties pay to company performance. The specific terms—110,294 shares at $0.17 strike, exercisable immediately and expiring in 2035—are disclosed exactly in the filing.

Compensation Analyst

The grant converts $18,750 of fees into a sizable option position at a $0.17 strike price.

The option count and strike price are explicit: 110,294 shares at $0.17 per share, issued 09/30/2025. This quantifies the director's incremental equity exposure and shows the company used its equity plan to settle director compensation for the recent quarter. The filing also reports post-transaction direct beneficial ownership of 1,164,025 shares, providing a clear baseline for the director's current stake.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Bray Christina Elaine

(Last) (First) (Middle)

14921 CHESTNUT ST.

(Street)

WESTMINSTER CA 92683

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLARGO, INC. [ BLGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.17	09/30/2025		A		110,294		09/30/2025	09/30/2035	Common Stock	110,294	(1)	1,164,025	D

Explanation of Responses:

1. This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan.

	/s/ John R. Browning, attorney-in-fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BLGO director Christina Elaine Bray receive on 09/30/2025?

She received an option to purchase 110,294 shares of Biolargo common stock at a $0.17 exercise price, exercisable 09/30/2025 and expiring 09/30/2035.

Why was the option granted to the director?

The Form 4 states the option was issued as payment for $18,750 in fees due to the reporting person for board services, under the issuer's 2024 Equity Incentive Plan.

How many Biolargo shares does the reporting person own after the grant?

After the reported transaction, the reporting person beneficially owns 1,164,025 shares, held directly.

When was this Form 4 filed and who signed it?

The filing shows execution dated 10/02/2025 and is signed by John R. Browning, attorney-in-fact for the reporting person.

Under which plan was the option issued?

The option was issued pursuant to the issuer's 2024 Equity Incentive Plan as stated in the filing.